Anderson KC - Search Results

1

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC; Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Richardson PG, et al. Among authors: anderson kc. N Engl J Med. 2005 Jun 16;352(24):2487-98. doi: 10.1056/NEJMoa043445. N Engl J Med. 2005. PMID: 15958804 Free article. Clinical Trial.

2

Multiple Myeloma: New Insights and Therapeutic Approaches.

Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Anderson KC, et al. Hematology Am Soc Hematol Educ Program. 2000:147-165. doi: 10.1182/asheducation-2000.1.147. Hematology Am Soc Hematol Educ Program. 2000. PMID: 11701540

3

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.

Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC. Chauhan D, et al. Among authors: anderson kc. Oncogene. 2002 Feb 21;21(9):1346-58. doi: 10.1038/sj.onc.1205205. Oncogene. 2002. PMID: 11857078

4

NF-kappa B as a therapeutic target in multiple myeloma.

Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. Hideshima T, et al. Among authors: anderson kc. J Biol Chem. 2002 May 10;277(19):16639-47. doi: 10.1074/jbc.M200360200. Epub 2002 Feb 28. J Biol Chem. 2002. PMID: 11872748 Free article.

5

Arsenic trioxide in multiple myeloma: rationale and future directions.

Anderson KC, Boise LH, Louie R, Waxman S. Anderson KC, et al. Cancer J. 2002 Jan-Feb;8(1):12-25. doi: 10.1097/00130404-200201000-00003. Cancer J. 2002. PMID: 11895198 Review.

6

CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.

Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KC. Treon SP, et al. Among authors: anderson kc. J Immunother. 2002 Jan-Feb;25(1):72-81. doi: 10.1097/00002371-200201000-00008. J Immunother. 2002. PMID: 11924912 Clinical Trial.

7

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC. Mitsiades N, et al. Among authors: anderson kc. Blood. 2002 Jun 1;99(11):4079-86. doi: 10.1182/blood.v99.11.4079. Blood. 2002. PMID: 12010810 Free article.

8

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Mitsiades N, et al. Among authors: anderson kc. Blood. 2002 Jun 15;99(12):4525-30. doi: 10.1182/blood.v99.12.4525. Blood. 2002. PMID: 12036884 Free article.

9

Cytokines modulate telomerase activity in a human multiple myeloma cell line.

Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC. Akiyama M, et al. Among authors: anderson kc. Cancer Res. 2002 Jul 1;62(13):3876-82. Cancer Res. 2002. PMID: 12097303 Retracted.

10

Novel therapies for multiple myeloma.

Ryoo JJ, Cole CE, Anderson KC. Ryoo JJ, et al. Among authors: anderson kc. Blood Rev. 2002 Sep;16(3):167-74. doi: 10.1016/s0268-960x(02)00009-7. Blood Rev. 2002. PMID: 12163002 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,203 results

Search Page